Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Munich, Germany.
Mult Scler. 2011 Apr;17(4):495-7. doi: 10.1177/1352458510390069. Epub 2010 Dec 9.
We report a 55-year-old male patient with secondary progressive multiple sclerosis who developed an acute febrile syndrome with fever, neutrophilia and tender erythematous plaques and papules on his upper extremities after his fifth mitoxantrone infusion. Infectious, haematological and rheumatological diseases were ruled out, but skin biopsy showed neutrophilic infiltrations in the dermis consistent with Sweet's syndrome. Treatment with oral corticosteroids led to prompt improvement of systemic and cutaneous symptoms. To our knowledge, this is the first report of a patient with Sweet's syndrome after mitoxantrone therapy. Clinicians should be aware of Sweet's syndrome in patients with otherwise unexplained acute febrile illness and erythematous skin rash in association with mitoxantrone therapy. Skin biopsy helped to exclude other diseases and confirmed Sweet's syndrome.
我们报告了一例 55 岁男性多发性硬化症继发进展患者,在第五次米托蒽醌输注后出现急性发热综合征,伴有发热、中性粒细胞增多和上肢红斑性斑块和丘疹。排除了感染性、血液学和风湿性疾病,但皮肤活检显示真皮中有中性粒细胞浸润,符合Sweet 综合征。口服皮质类固醇治疗迅速改善了全身和皮肤症状。据我们所知,这是首例米托蒽醌治疗后发生 Sweet 综合征的患者。临床医生应注意到,在伴有米托蒽醌治疗的不明原因急性发热和红斑性皮疹的患者中存在 Sweet 综合征。皮肤活检有助于排除其他疾病,并明确了 Sweet 综合征的诊断。